Delay in Passing Amendment to Tobacco Business Law Raises Concerns

Dec.19.2024
Delay in Passing Amendment to Tobacco Business Law Raises Concerns
Congressional delay on a bill treating synthetic nicotine cigarettes like traditional ones may lead to serious regulation gaps.

According to N.News, the congressional passage of the amendment to the Tobacco Control Act, which would treat and regulate synthetic nicotine cigarettes the same as traditional cigarettes, is expected to be delayed until next year due to the ongoing presidential impeachment proceedings starting this winter. The pause in discussions regarding this amendment may result in more serious regulatory gaps.


The current Tobacco Control Law does not classify liquid cigarettes containing synthetic nicotine as cigarettes. Industry insiders have long been calling for synthetic nicotine to be classified as cigarettes as well. They argue that synthetic nicotine cigarettes are equally harmful to the human body as traditional cigarettes, and therefore should be subject to the same regulations to maintain fairness.


According to a study released by the South Korean Ministry of Health and Welfare on November 27, there are 45 harmful substances (such as carcinogens and reproductive toxicants) detected in synthetic nicotine solution, exceeding the 41 found in equivalent amounts of natural nicotine solution. The Ministry of Health and Welfare has communicated its position to the Ministry of Planning and Finance, stating that regulating synthetic nicotine under the Tobacco Business Act is appropriate.


In 2020, National Forces Party lawmaker Park Seong-hoon proposed a draft amendment to the Tobacco Business Act. In 2023, the National Assembly's Planning and Finance Committee also discussed improving the system for synthetic nicotine electronic cigarettes. Currently, in the 22nd National Assembly, 10 draft amendments related to the Tobacco Business Act are pending review.


On November 27th, the Economic and Fiscal Subcommittee of the House Planning and Budget Committee held a meeting to discuss an amendment and plan to hold a public hearing. However, due to the impeachment of President Yoon, the parliament has effectively become paralyzed, and the public hearing on the Tobacco Industry Law scheduled for earlier this month has been indefinitely postponed.


The delayed passage of the amendment to the Tobacco Business Act is expected to prolong the long-term social consequences of the legislative vacuum. Due to the lack of taxation on synthetic nicotine cigarettes, which are cheaper than regular cigarettes and have almost no sales restrictions, they are easily accessible to teenagers. Data from the Korean Centers for Disease Control and Prevention shows that around 70% of teenage smokers start smoking through e-cigarettes.


Additionally, synthetic nicotine cigarettes are not taxed, leading to their 30ml e-liquid supplement being sold online for less than 10,000 Korean won (approximately 7 US dollars).


Furthermore, tax losses and cases of abuse continue to emerge due to regulatory loopholes. The Korean e-Liquid Safety Association estimates that the annual amount of tax evasion for synthetic nicotine e-cigarettes could be as high as approximately 1.6 trillion Korean won (1.1 billion US dollars). Some importers falsely report natural nicotine as synthetic nicotine in order to save on taxes. According to data from the Korea Customs Service, there were 110 cases of false declaration from November 2022 to July 2023.


A tobacco industry official stated that...


South Korea is the only OECD country that has not classified synthetic nicotine as a tobacco product. This is not in line with international standards and needs to be improved. Urgent legislative measures are needed to protect young people, ensure tax security, and promote fairness in the industry.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Patent Reveals China Tobacco Hubei Industrial Testing Animal Model for Heated Tobacco Safety Evaluation
Patent Reveals China Tobacco Hubei Industrial Testing Animal Model for Heated Tobacco Safety Evaluation
China Tobacco Hubei Industrial Co., Ltd. has published a patent describing a laboratory method to evaluate the reproductive and developmental safety of heated tobacco products using non-human animal exposure models. The approach introduces a structured toxicological testing framework that could support safety verification, quality control, and regulatory evidence generation for heated tobacco products.
Mar.09
Michigan Senate Bill 786 Seeks to Ban Sale of Vapes With Metal Heating Elements
Michigan Senate Bill 786 Seeks to Ban Sale of Vapes With Metal Heating Elements
Michigan lawmakers introduced Senate Bill 786 on February 18, 2026, proposing to prohibit the sale or transfer of vapor products that contain heating elements unless those elements are made of or encased in glass or ceramic materials
Regulations
Feb.21
Russian Lawmaker Says Vape Circulation Licensing Will Be Regulated by Law in the Coming Months
Russian Lawmaker Says Vape Circulation Licensing Will Be Regulated by Law in the Coming Months
Alexander Tolmachev, deputy chairman of the Russian State Duma Committee on Youth Policy, said the issue of licensing vape circulation will be resolved at the legislative level in the coming months. He said a significant share of such products currently on the market are counterfeit, that their real nicotine concentration may be several times higher than stated, and that the composition of the liquid is unknown.
Mar.18 by 2FIRSTS.ai
Azerbaijan’s Milli Majlis to hold public hearings on e-cigarette use in the 2026 spring session
Azerbaijan’s Milli Majlis to hold public hearings on e-cigarette use in the 2026 spring session
Azerbaijan’s Milli Majlis will hold public hearings regarding the use of e-cigarettes. The topic has been included in the 2026 spring session work plan of the Milli Majlis Committee on Agrarian Policy. During the spring session, the committee plans to convene a public hearing titled “Health is our goal: an end to e-cigarettes.”
Jan.23 by 2FIRSTS.ai
Special Report|Russia scales back anti-vaping drive, limits ban to single-region trial
Special Report|Russia scales back anti-vaping drive, limits ban to single-region trial
After months of debate, Russian lawmakers have retreated from plans for a nationwide vaping ban, opting instead for a single-region pilot. The shift reflects pressure from business groups and fiscal authorities, amid warnings that sweeping prohibitions could fuel illegal trade while undermining efforts to regulate the market.
Jan.22